Heart-lung Interactions Determine Right Ventricular Function In The Perinatal Period.
Funder
National Health and Medical Research Council
Funding Amount
$421,980.00
Summary
Birth, and the ensuing stress of newborn life, requires the heart to dramatically increase its level of functioning. Understanding how this process occurs remains a key problem as the heart lacks any ability to increase its level of functioning immediately before birth. Failure to effect this increase in heart function promptly at birth has serious implications for the well being of the newborn and represents a major problem in newborn medicine. Of the 250,000 babies born each year in Australia, ....Birth, and the ensuing stress of newborn life, requires the heart to dramatically increase its level of functioning. Understanding how this process occurs remains a key problem as the heart lacks any ability to increase its level of functioning immediately before birth. Failure to effect this increase in heart function promptly at birth has serious implications for the well being of the newborn and represents a major problem in newborn medicine. Of the 250,000 babies born each year in Australia, as many as 5,000 require intensive care primarily for cardiorespiratory complications. Accurate diagnosis and effective treatment of these infants demands knowledge of the normal heart adaptations that accompany birth, adaptations that are critically linked to the way in which the heart and the lungs interact. This project investigates how interactions between the heart and the lungs determines heart function throughout life. By understanding this process we will provide essential information that will aid the diagnosis and treatment of sick neonates undergoing intensive care.Read moreRead less
Therapeutic Approaches To Circumvent NO• Resistance In The Type 2 Diabetic Heart And Vasculature
Funder
National Health and Medical Research Council
Funding Amount
$563,337.00
Summary
Type 2 diabetes (T2D) is Australia’s fastest growing chronic disease, affecting almost 2 million Australians (who face poor cardiovascular health outcomes). We have discovered an exciting new avenue that may potentially more effectively counteract heart and blood vessel disorders in T2D patients in an acute cardiovascular emergency, of substantial clinical importance.
NOVEL CGMP-BASED THERAPIES PREVENT LEFT VENTRICULAR REMODELLING
Funder
National Health and Medical Research Council
Funding Amount
$533,433.00
Summary
Over 300,000 Australians are affected by heart failure. Current drugs for cardiac remodelling (the decline in heart pumping function and changed structure that precede heart failure) slow but not reverse disease progression. We have identified a new, nitrovasodilator-based therapy superior to those currently available. We propose it represents a more effective treatment for reversing abnormalities in both structure and function in the remodelled heart, preventing or delaying heart failure.
Benefit Of 2D-strain Surveillance In Improving Cardiovascular Outcomes In Cancer Patients Undergoing Cardiotoxic Chemotherapy
Funder
National Health and Medical Research Council
Funding Amount
$2,391,979.00
Summary
Cancer survivors are susceptible to heart failure (HF) caused by heart muscle damage from chemotherapy. The current testing for this problem is based on a measure that cannot identify minor changes of cardiac function. Cardiac strain is a sensitive new marker of cardiac function which is predictive of overt dysfunction & HF. This study seeks to identify whether strain can be used to assign treatments that lead to improved cardiac function and are eventually associated with a reduction in HF.
Clinical Utility Of New Non-invasive Assessments Of Left Ventricular Function.
Funder
National Health and Medical Research Council
Funding Amount
$48,361.00
Summary
This project involves a series of studies that investigate the use of new ultrasound measurements of heart function in order to assess whether or nor they make a meaningful contribution to patient management, both in terms of diagnosis and monitoring of treatments. Major studies include: 1) Detection and prevention of early heart disease in patients who are undergoing toxic chemotherapy for cancer; and 2) Investigation and treatment of patients with a high blood pressure response to exercise.
I am a cardiology research scientist investigating the differences between physiological (“good”) and pathological (“bad”) heart growth- cardiac hypertrophy. In general, heart failure research and therapy has concentrated on identifying and inhibiting pathological processes. In contrast, my research is unique because it has focused on activating physiological pathways (elevated in the athlete’s heart) in the failing heart as a potential new strategy for the treatment of heart failure and atrial ....I am a cardiology research scientist investigating the differences between physiological (“good”) and pathological (“bad”) heart growth- cardiac hypertrophy. In general, heart failure research and therapy has concentrated on identifying and inhibiting pathological processes. In contrast, my research is unique because it has focused on activating physiological pathways (elevated in the athlete’s heart) in the failing heart as a potential new strategy for the treatment of heart failure and atrial fibrillation.Read moreRead less